Key Highlights

  • Loss per share was USD 0.56 against an estimate of a USD 0.55 loss.
  • Net loss was USD 28.82 million, against USD 21.53 million a year earlier.
  • The company announced the wind-down of its AlloNK development program on October 27, 2026.
  • Cash and short-term investments were USD 319.1 million at September 30.

Artiva Biotherapeutics (NASDAQ:ARTV) reported a third quarter 2026 loss per share of USD 0.56, against an estimate of a USD 0.55 loss and a USD 0.88 loss in the third quarter of 2025. Net loss was USD 28.82 million, compared with USD 21.53 million.

The loss from operations was USD 31.95 million, compared with USD 22.90 million. On October 27, 2026, the company announced the wind-down of its AlloNK development program, which includes a plan to reduce its workforce, as it conducts a process to explore strategic alternatives to maximize stockholder value.

Operating Expenses and Other Income

Research and development expenses were USD 25.99 million, compared with USD 17.63 million, an increase of USD 8.4 million that the filing attributes primarily to a USD 5.5 million increase in external Research and Development expense, mainly AlloNK product candidate development costs, and a USD 2.8 million increase in internal research and development expense. General and administrative expenses were USD 5.96 million, compared with USD 5.26 million. Total operating expenses were USD 31.95 million, against USD 22.90 million.

Interest income was USD 3.14 million. Other income, net, was USD 3.1 million, compared with USD 1.4 million, and the filing reports an unrealized loss on investments of USD 1.2 million, compared with an unrealized gain of USD 0.1 million.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 77.34 million, compared with USD 63.09 million, and the loss per share was USD 2.01, against USD 2.59. Total operating expenses were USD 83.27 million, against USD 67.88 million, and research and development expenses were USD 67.23 million, against USD 52.55 million.

General and administrative expenses for the nine months were USD 16.05 million, against USD 15.33 million. Share-based compensation for the nine months was USD 6.26 million, against USD 5.23 million.

Wind-Down, Liquidity and Agreements

As of September 30, 2026, the company had cash, cash equivalents and short-term investments of USD 319.1 million and an accumulated Deficit of USD 407.9 million. During the nine months, the company used USD 69.8 million of cash for operating activities. The filing states that the company continues to conduct clinical, regulatory, scientific and intellectual property activities following the announcement, and describes the wind-down as a non-recognized subsequent event.

In May 2026, the company completed a public offering of common stock, with gross proceeds of USD 300.0 million, including the issuance of pre-funded warrants to purchase 2,170,138 shares at USD 11.5199 per warrant. After USD 17.3 million of offering costs, net proceeds were USD 282.7 million.

The filing describes license agreements with GC Cell entered into in November 2019, October 2020, March 2021 and December 2022, and a Research Services Agreement entered into with GC Cell in August 2020, under which GC Cell provides research services. Research and development expenses include small related party amounts.

The filing also notes that its employee stock purchase plan begins a new offering each January 16 and July 16.

Artiva Biotherapeutics Q3 2026 Earnings: Key Takeaways

Artiva Biotherapeutics reported a third quarter 2026 loss per share of USD 0.56 and a net loss of USD 28.82 million. The company announced the wind-down of its AlloNK program, and cash, cash equivalents and short-term investments were USD 319.1 million.